IEX-2014.03.31-10Q
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
Form 10-Q
|
| |
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the quarterly period ended March 31, 2014 |
OR
|
| |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number 1-10235
IDEX CORPORATION
(Exact Name of Registrant as Specified in its Charter)
|
| | |
Delaware | | 36-3555336 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| |
1925 West Field Court, Lake Forest, Illinois | | 60045 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number: (847) 498-7070
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes þ No ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes þ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
|
| | | | | | |
Large accelerated filer þ | | Accelerated filer ¨ | | Non-accelerated filer ¨ | | Smaller reporting company ¨ |
| | | | (Do not check if a smaller reporting company) |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No þ
Number of shares of common stock of IDEX Corporation outstanding as of April 23, 2014: 80,618,840.
TABLE OF CONTENTS
|
| | |
| |
Item 1. | | |
| | |
| | |
| | |
| | |
| | |
| | |
Item 2. | | |
| | |
| | |
| | |
| | |
| | |
Item 3. | | |
Item 4. | | |
| |
| |
Item 1. | | |
Item 2. | | |
Item 6. | | |
| |
| |
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
IDEX CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except share and per share amounts)
(unaudited)
|
| | | | | | | |
| March 31, 2014 | | December 31, 2013 |
ASSETS | | | |
Current assets | | | |
Cash and cash equivalents | $ | 458,383 |
| | $ | 439,629 |
|
Receivables, less allowance for doubtful accounts of $6,202 at March 31, 2014 and $5,841 at December 31, 2013 | 287,903 |
| | 253,226 |
|
Inventories — net | 244,175 |
| | 230,967 |
|
Other current assets | 72,915 |
| | 67,131 |
|
Total current assets | 1,063,376 |
| | 990,953 |
|
Property, plant and equipment — net | 216,045 |
| | 213,488 |
|
Goodwill | 1,349,926 |
| | 1,349,456 |
|
Intangible assets — net | 300,710 |
| | 311,227 |
|
Other noncurrent assets | 21,765 |
| | 22,453 |
|
Total assets | $ | 2,951,822 |
| | $ | 2,887,577 |
|
LIABILITIES AND SHAREHOLDERS’ EQUITY | | | |
Current liabilities | | | |
Trade accounts payable | $ | 149,045 |
| | $ | 133,312 |
|
Accrued expenses | 163,543 |
| | 150,751 |
|
Current portion of long-term debt and short-term borrowings | 1,393 |
| | 1,871 |
|
Dividends payable | — |
| | 18,675 |
|
Total current liabilities | 313,981 |
| | 304,609 |
|
Long-term borrowings | 778,852 |
| | 772,005 |
|
Deferred income taxes | 146,643 |
| | 144,908 |
|
Other noncurrent liabilities | 91,348 |
| | 93,066 |
|
Total liabilities | 1,330,824 |
| | 1,314,588 |
|
Commitments and contingencies |
| |
|
Shareholders’ equity | | | |
Preferred stock: | | | |
Authorized: 5,000,000 shares, $.01 per share par value; Issued: None | — |
| | — |
|
Common stock: | | | |
Authorized: 150,000,000 shares, $.01 per share par value | | | |
Issued: 89,420,137 shares at March 31, 2014 and 89,154,190 shares at December 31, 2013 | 894 |
| | 892 |
|
Additional paid-in capital | 622,092 |
| | 607,766 |
|
Retained earnings | 1,368,288 |
| | 1,293,740 |
|
Treasury stock at cost: 8,545,237 shares at March 31, 2014 and 7,958,510 shares at December 31, 2013 | (368,851 | ) | | (326,104 | ) |
Accumulated other comprehensive loss | (1,425 | ) | | (3,305 | ) |
Total shareholders’ equity | 1,620,998 |
| | 1,572,989 |
|
Total liabilities and shareholders’ equity | $ | 2,951,822 |
| | $ | 2,887,577 |
|
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
(unaudited)
|
| | | | | | | | |
| | Three Months Ended March 31, |
| | 2014 | | 2013 |
Net sales | | $ | 543,996 |
| | $ | 494,448 |
|
Cost of sales | | 299,576 |
| | 282,451 |
|
Gross profit | | 244,420 |
| | 211,997 |
|
Selling, general and administrative expenses | | 130,585 |
| | 117,285 |
|
Operating income | | 113,835 |
| | 94,712 |
|
Other income — net | | 844 |
| | 1,279 |
|
Interest expense | | 10,457 |
| | 10,557 |
|
Income before income taxes | | 104,222 |
| | 85,434 |
|
Provision for income taxes | | 29,674 |
| | 24,134 |
|
Net income | | $ | 74,548 |
| | $ | 61,300 |
|
| | | | |
Basic earnings per common share | | $ | 0.92 |
| | $ | 0.74 |
|
Diluted earnings per common share | | $ | 0.91 |
| | $ | 0.74 |
|
| | | | |
Share data: | | | | |
Basic weighted average common shares outstanding | | 80,527 |
| | 82,197 |
|
Diluted weighted average common shares outstanding | | 81,575 |
| | 83,152 |
|
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands)
(unaudited)
|
| | | | | | | |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Net income | $ | 74,548 |
| | $ | 61,300 |
|
Other comprehensive income (loss) | | | |
Reclassification adjustments for derivatives, net of tax | 1,157 |
| | 1,190 |
|
Pension and other postretirement adjustments, net of tax | 439 |
| | 1,273 |
|
Cumulative translation adjustment | 284 |
| | (27,253 | ) |
Other comprehensive income (loss) | 1,880 |
| | (24,790 | ) |
Comprehensive income | $ | 76,428 |
| | $ | 36,510 |
|
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(in thousands except share and per share amounts)
(unaudited)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | Accumulated Other Comprehensive Income (Loss) | | | | |
| Common Stock and Additional Paid-In Capital | | Retained Earnings | | Cumulative Translation Adjustment | | Retirement Benefits Adjustment | | Cumulative Unrealized Gain (Loss) on Derivatives | | Treasury Stock | | Total Shareholders’ Equity |
Balance, December 31, 2013 | $ | 608,658 |
| | $ | 1,293,740 |
| | $ | 52,211 |
| | $ | (23,857 | ) | | $ | (31,659 | ) | | $ | (326,104 | ) | | $ | 1,572,989 |
|
Net income | — |
| | 74,548 |
| | — |
| | — |
| | — |
| | — |
| | 74,548 |
|
Cumulative translation adjustment | — |
| | — |
| | 284 |
| | — |
| | — |
| | — |
| | 284 |
|
Pension and other postretirement adjustments (net of tax of $240) | — |
| | — |
| | — |
| | 439 |
| | — |
| | — |
| | 439 |
|
Amortization of forward starting swaps (net of tax of $663) | — |
| | — |
| | — |
| | — |
| | 1,157 |
| | — |
| | 1,157 |
|
Issuance of 278,067 shares of common stock from issuance of unvested shares, exercise of stock options and deferred compensation plans (net of tax of $1,875) | 9,079 |
| | — |
| | — |
| | — |
| | — |
| | — |
| | 9,079 |
|
Repurchase of 551,148 shares of common stock | — |
| | — |
| | — |
| | — |
| | — |
| | (40,133 | ) | | (40,133 | ) |
Shares surrendered for tax withholding | — |
| | — |
| | — |
| | — |
| | — |
| | (2,614 | ) | | (2,614 | ) |
Share-based compensation | 5,249 |
| | — |
| | — |
| | — |
| | — |
| | — |
| | 5,249 |
|
Balance, March 31, 2014 | $ | 622,986 |
| | $ | 1,368,288 |
| | $ | 52,495 |
| | $ | (23,418 | ) | | $ | (30,502 | ) | | $ | (368,851 | ) | | $ | 1,620,998 |
|
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited) |
| | | | | | | |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Cash flows from operating activities | | | |
Net income | $ | 74,548 |
| | $ | 61,300 |
|
Adjustments to reconcile net income to net cash provided by operating activities | | | |
Depreciation and amortization | 8,394 |
| | 8,948 |
|
Amortization of intangible assets | 10,863 |
| | 10,891 |
|
Amortization of debt issuance expenses | 429 |
| | 425 |
|
Share-based compensation expense | 6,312 |
| | 5,612 |
|
Deferred income taxes | (748 | ) | | (117 | ) |
Excess tax benefit from share based compensation | (2,925 | ) | | (2,439 | ) |
Non-cash interest expense associated with forward starting swaps | 1,820 |
| | 1,872 |
|
Changes in: | | | |
Receivables | (33,910 | ) | | (14,843 | ) |
Inventories | (12,605 | ) | | (3,115 | ) |
Other current assets | (6,285 | ) | | (3,513 | ) |
Trade accounts payable | 15,392 |
| | 6,303 |
|
Accrued expenses | 14,419 |
| | 1,043 |
|
Other — net | (1,519 | ) | | (172 | ) |
Net cash flows provided by operating activities | 74,185 |
| | 72,195 |
|
Cash flows from investing activities | | | |
Cash purchases of property, plant and equipment | (10,809 | ) | | (7,625 | ) |
Acquisition of businesses, net of cash acquired | — |
| | (34,648 | ) |
Other — net | 21 |
| | (57 | ) |
Net cash flows used in investing activities | (10,788 | ) | | (42,330 | ) |
Cash flows from financing activities | | | |
Borrowings under revolving facilities for acquisitions | — |
| | 34,648 |
|
Borrowings under revolving facilities | 20,014 |
| | 5,438 |
|
Payments under revolving facilities | (13,617 | ) | | (305 | ) |
Dividends paid | (18,628 | ) | | (16,575 | ) |
Proceeds from stock option exercises | 6,154 |
| | 10,758 |
|
Excess tax benefit from stock-based compensation | 2,925 |
| | 2,439 |
|
Purchase of common stock | (37,537 | ) | | (33,115 | ) |
Unvested shares surrendered for tax withholding | (2,614 | ) | | (1,735 | ) |
Net cash flows provided by (used in) financing activities | (43,303 | ) | | 1,553 |
|
Effect of exchange rate changes on cash and cash equivalents | (1,340 | ) | | (9,237 | ) |
Net increase in cash | 18,754 |
| | 22,181 |
|
Cash and cash equivalents at beginning of year | 439,629 |
| | 318,864 |
|
Cash and cash equivalents at end of period | $ | 458,383 |
| | $ | 341,045 |
|
| | | |
Supplemental cash flow information | | | |
Cash paid for: | | | |
Interest | $ | 85 |
| | $ | 545 |
|
Income taxes | 17,835 |
| | 7,002 |
|
See Notes to Condensed Consolidated Financial Statements
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
1. Basis of Presentation and Significant Accounting Policies
The Condensed Consolidated Financial Statements of IDEX Corporation (“IDEX” or the “Company”) have been prepared in accordance with the accounting principles generally accepted in the United States of America applicable to interim financial information and the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, that the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the entire year.
The Condensed Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013.
2. Acquisitions
All of the Company’s acquisitions have been accounted for under Accounting Standards Codification (“ASC”) 805, Business Combinations. Accordingly, the accounts of the acquired companies, after adjustments to reflect fair values assigned to assets and liabilities, have been included in the consolidated financial statements from their respective dates of acquisition.
2013 Acquisitions
On March 18, 2013, the Company acquired the assets of FTL Seals Technology, Ltd (“FTL”). FTL specializes in the design and application of high integrity rotary seals, specialty bearings, and other custom products for the oil & gas, mining, power generation, and marine markets. Located in Leeds, England, FTL, along with Precision Polymer Engineering (“PPE”), operates within the Health & Science Technologies segment as part of the Sealing Solutions group and will expand the range of PPE’s technology expertise and markets served. FTL was acquired for an aggregate purchase price of $34.5 million (£23.1 million) in cash. The entire purchase price was funded with borrowings under the Company’s revolving credit facility. Goodwill and intangible assets recognized as part of this transaction were $18.0 million and $13.0 million, respectively. The $18.0 million of goodwill is not deductible for tax purposes.
The Company incurred $0.5 million of acquisition-related transaction costs in the three months ended March 31, 2014. These costs were recorded in selling, general and administrative expense and were related to completed transactions, pending transactions and potential transactions, including transactions that ultimately were not completed.
3. Business Segments
The Company has three reportable business segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products.
The Fluid & Metering Technologies segment designs, produces and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems and provides flow monitoring and other services for the water and wastewater industries. The Health & Science Technologies segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, semiconductor, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets, and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications. The Fire & Safety/Diversified Products segment produces firefighting pumps and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications, and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world.
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
Information on the Company’s business segments is presented below, based on the nature of products and services offered. The Company evaluates performance based on several factors, of which operating income is the primary financial measure. Intersegment sales are accounted for at fair value as if the sales were to third parties.
|
| | | | | | | |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Net sales: | | | |
Fluid & Metering Technologies: | | | |
External customers | $ | 223,007 |
| | $ | 211,407 |
|
Intersegment sales | 354 |
| | 348 |
|
Total group sales | 223,361 |
| | 211,755 |
|
Health & Science Technologies: | | | |
External customers | 183,892 |
| | 171,674 |
|
Intersegment sales | 2,483 |
| | 1,194 |
|
Total group sales | 186,375 |
| | 172,868 |
|
Fire & Safety/Diversified Products: | | | |
External customers | 137,097 |
| | 111,367 |
|
Intersegment sales | 187 |
| | 146 |
|
Total group sales | 137,284 |
| | 111,513 |
|
Intersegment elimination | (3,024 | ) | | (1,688 | ) |
Total net sales | $ | 543,996 |
| | $ | 494,448 |
|
Operating income: | | | |
Fluid & Metering Technologies | $ | 56,407 |
| | $ | 48,079 |
|
Health & Science Technologies | 36,229 |
| | 32,267 |
|
Fire & Safety/Diversified Products | 39,648 |
| | 28,232 |
|
Corporate office and other | (18,449 | ) | | (13,866 | ) |
Total operating income | 113,835 |
| | 94,712 |
|
Interest expense | 10,457 |
| | 10,557 |
|
Other income - net | 844 |
| | 1,279 |
|
Income before income taxes | $ | 104,222 |
| | $ | 85,434 |
|
|
| | | | | | | |
| March 31, 2014 | | December 31, 2013 |
Assets: | | | |
Fluid & Metering Technologies | $ | 1,031,728 |
| | $ | 1,025,352 |
|
Health & Science Technologies | 1,132,689 |
| | 1,113,546 |
|
Fire & Safety/Diversified Products | 515,992 |
| | 484,139 |
|
Corporate office | 271,413 |
| | 264,540 |
|
Total assets | $ | 2,951,822 |
| | $ | 2,887,577 |
|
4. Earnings Per Common Share
Earnings per common share (“EPS”) are computed by dividing net income by the weighted average number of shares of common stock (basic) plus common stock equivalents outstanding (diluted) during the period. Common stock equivalents consist of stock options, which have been included in the calculation of weighted average shares outstanding using the treasury stock method, unvested shares, performance share units, and shares issuable in connection with certain deferred compensation agreements (“DCUs”).
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
ASC 260 “Earnings Per Share” provides that all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding unvested shares are participating securities. Accordingly, earnings per common share are computed using the more dilutive of the treasury stock method and the two-class method prescribed by ASC 260. For the purposes of calculating diluted EPS, net income attributable to common shareholders was reduced by $0.5 million and $0.3 million for the three months ended March 31, 2014 and 2013, respectively.
Basic weighted average shares reconciles to diluted weighted average shares as follows:
|
| | | | | |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Basic weighted average common shares outstanding | 80,527 |
| | 82,197 |
|
Dilutive effect of stock options, unvested shares, performance share units and DCUs | 1,048 |
| | 955 |
|
Diluted weighted average common shares outstanding | 81,575 |
| | 83,152 |
|
Options to purchase approximately 0.5 million and 0.6 million shares of common stock for the three months ended March 31, 2014 and 2013, respectively, were not included in the computation of diluted EPS because the effect of their inclusion would be antidilutive.
5. Inventories
The components of inventories as of March 31, 2014 and December 31, 2013 were:
|
| | | | | | | |
| March 31, 2014 | | December 31, 2013 |
Raw materials and component parts | $ | 139,522 |
| | $ | 133,470 |
|
Work in process | 43,400 |
| | 41,895 |
|
Finished goods | 61,253 |
| | 55,602 |
|
Total | $ | 244,175 |
| | $ | 230,967 |
|
Inventories are stated at the lower of cost or market. Cost, which includes material, labor, and factory overhead, is determined on a FIFO basis.
6. Goodwill and Intangible Assets
The changes in the carrying amount of goodwill for the three months ended March 31, 2014, by reportable business segment, were as follows:
|
| | | | | | | | | | | | | | | |
| Fluid & Metering Technologies | | Health & Science Technologies | | Fire & Safety/ Diversified Products | | Total |
Balance at December 31, 2013 | $ | 528,044 |
| | $ | 571,675 |
| | $ | 249,737 |
| | $ | 1,349,456 |
|
Foreign currency translation | (105 | ) | | 618 |
| | (43 | ) | | 470 |
|
Balance at March 31, 2014 | $ | 527,939 |
| | $ | 572,293 |
| | $ | 249,694 |
| | $ | 1,349,926 |
|
ASC 350 “Goodwill and Other Intangible Assets” requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. Annually on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. The Company did not consider there to be any triggering event that would require an interim impairment assessment, therefore none of the goodwill or other acquired intangible assets with indefinite lives were tested for impairment during the three months ended March 31, 2014. Based on the results of our annual impairment test at October 31, 2013, all reporting units had a fair value that was significantly in excess of carrying value, except for our IDEX Optics and Photonics ("IOP") reporting unit, which had a fair value approximately 10% greater than the carrying value. The IOP reporting
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
unit was written down to its fair value in 2012 as a result of our annual goodwill impairment testing and, thus, the fair value continues to be near the carrying value.
The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at March 31, 2014 and December 31, 2013:
|
| | | | | | | | | | | | | | | | | | | | | | | | | |
| At March 31, 2014 | | | | At December 31, 2013 |
| Gross Carrying Amount | | Accumulated Amortization | | Net | | Weighted Average Life | | Gross Carrying Amount | | Accumulated Amortization | | Net |
Amortized intangible assets: | | | | | | | | | | | | | |
Patents | $ | 9,955 |
| | $ | (4,658 | ) | | $ | 5,297 |
| | 11 | | $ | 10,673 |
| | $ | (5,179 | ) | | $ | 5,494 |
|
Trade names | 104,606 |
| | (29,939 | ) | | 74,667 |
| | 16 | | 104,582 |
| | (28,310 | ) | | 76,272 |
|
Customer relationships | 242,933 |
| | (127,878 | ) | | 115,055 |
| | 10 | | 242,674 |
| | (121,092 | ) | | 121,582 |
|
Non-compete agreements | 3,175 |
| | (2,744 | ) | | 431 |
| | 3 | | 3,769 |
| | (3,272 | ) | | 497 |
|
Unpatented technology | 75,489 |
| | (34,853 | ) | | 40,636 |
| | 11 | | 75,528 |
| | (32,905 | ) | | 42,623 |
|
Other | 6,999 |
| | (4,475 | ) | | 2,524 |
| | 10 | | 6,958 |
| | (4,299 | ) | | 2,659 |
|
Total amortized intangible assets | 443,157 |
| | (204,547 | ) | | 238,610 |
| | | | 444,184 |
| | (195,057 | ) | | 249,127 |
|
Unamortized intangible assets: | | | | | | | | | | | | | |
Banjo trade name | 62,100 |
| | — |
| | 62,100 |
| | | | 62,100 |
| | — |
| | 62,100 |
|
Total intangible assets | $ | 505,257 |
| | $ | (204,547 | ) | | $ | 300,710 |
| | | | $ | 506,284 |
| | $ | (195,057 | ) | | $ | 311,227 |
|
The unamortized Banjo trade name is an indefinite lived intangible asset which is tested for impairment on an annual basis in accordance with ASC 350 or more frequently if events or changes in circumstances indicate that the asset might be impaired.
7. Accrued Expenses
The components of accrued expenses as of March 31, 2014 and December 31, 2013 were:
|
| | | | | | | |
| March 31, 2014 | | December 31, 2013 |
Payroll and related items | $ | 61,804 |
| | $ | 63,297 |
|
Management incentive compensation | 7,048 |
| | 20,949 |
|
Income taxes payable | 25,512 |
| | 11,746 |
|
Insurance | 8,995 |
| | 7,741 |
|
Warranty | 5,109 |
| | 4,888 |
|
Deferred revenue | 12,343 |
| | 9,455 |
|
Liability for uncertain tax positions | 950 |
| | 1,201 |
|
Accrued interest | 9,477 |
| | 1,354 |
|
Other | 32,305 |
| | 30,120 |
|
Total accrued expenses | $ | 163,543 |
| | $ | 150,751 |
|
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
8. Other Noncurrent Liabilities
The components of Other noncurrent liabilities as of March 31, 2014 and December 31, 2013 were:
|
| | | | | | | |
| March 31, 2014 | | December 31, 2013 |
Pension and retiree medical obligations | $ | 67,731 |
| | $ | 67,777 |
|
Liability for uncertain tax positions | 3,017 |
| | 4,624 |
|
Deferred revenue | 5,184 |
| | 5,578 |
|
Other | 15,416 |
| | 15,087 |
|
Total other noncurrent liabilities | $ | 91,348 |
| | $ | 93,066 |
|
9. Borrowings
Borrowings at March 31, 2014 and December 31, 2013 consisted of the following:
|
| | | | | | | |
| March 31, 2014 | | December 31, 2013 |
Revolving Facility | $ | 17,000 |
| | $ | 10,000 |
|
2.58% Senior Euro Notes, due June 2015 | 111,391 |
| | 111,505 |
|
4.5% Senior Notes, due December 2020 | 298,864 |
| | 298,828 |
|
4.2% Senior Notes, due December 2021 | 349,292 |
| | 349,272 |
|
Other borrowings | 3,698 |
| | 4,271 |
|
Total borrowings | 780,245 |
| | 773,876 |
|
Less current portion | 1,393 |
| | 1,871 |
|
Total long-term borrowings | $ | 778,852 |
| | $ | 772,005 |
|
The Company maintains a $700.0 million revolving credit facility (the "Revolving Facility") with a maturity date of June 27, 2016. Up to $75.0 million of the Revolving Facility is available for the issuance of letters of credit, and up to $25.0 million is available to the Company for swing line loans, available on a same-day basis.
Proceeds from the Revolving Facility are available for use towards working capital, acquisitions and other general corporate purposes, including refinancing existing debt of the Company and its subsidiaries.
Borrowings under the Revolving Facility bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, in each case, an applicable margin. Such applicable margin is based on the Company’s senior, unsecured, long-term debt rating and can range from .875% to 1.70%. Based on the Company’s credit rating at March 31, 2014, the applicable margin was 1.05%. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the maturity date of the borrowing, or quarterly from the effective date for borrowings exceeding three months. An annual Revolving Facility fee, also based on the Company’s credit rating, is currently 20 basis points and is payable quarterly.
At March 31, 2014, $17.0 million was outstanding under the Revolving Facility, with $7.9 million of outstanding letters of credit, resulting in net available borrowing capacity under the Revolving Facility at March 31, 2014 of approximately $675.1 million.
Other borrowings of $3.7 million at March 31, 2014 consisted primarily of debt at international locations maintained for working capital purposes. Interest is payable on the outstanding debt balances at rates ranging from 0.3% to 1.5% per annum.
There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and 2.58% Senior Euro Notes. The most restrictive financial covenants under these debt instruments require a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.25 to 1. At March 31, 2014, the Company was in compliance with both of these financial covenants. There are no financial covenants relating to the 4.5% Senior Notes or 4.2% Senior Notes; however, both are subject to cross-default provisions.
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
10. Derivative Instruments
The Company enters into cash flow hedges from time to time to reduce the exposure to variability in certain expected future cash flows. The type of cash flow hedges the Company enters into includes foreign currency contracts and interest rate exchange agreements that effectively convert a portion of floating-rate debt to fixed-rate debt and are designed to reduce the impact of interest rate changes on future interest expense.
The effective portion of gains or losses on interest rate exchange agreements is reported in accumulated other comprehensive income (loss) in shareholders’ equity and reclassified into net income in the same period or periods in which the hedged transaction affects net income. See Note 12 for the amount of loss reclassified into income for interest rate contracts for March 2014 and 2013. The remaining gain or loss in excess of the cumulative change in the present value of future cash flows or the hedged item, if any, is recognized into net income during the period of change.
Fair values relating to derivative financial instruments reflect the estimated amounts that the Company would receive or pay to sell or buy the contracts based on quoted market prices of comparable contracts at each balance sheet date. As of March 31, 2014 the Company did not have any interest rate contracts outstanding.
In 2010 and 2011 the Company entered into two separate forward starting interest rate contracts in anticipation of the issuance of the 4.2% Senior Notes and the 4.5% Senior Notes. The Company cash settled these two interest rate contracts in 2010 and 2011 for a total of $68.9 million, which is being amortized into interest expense over the 10 year term of the debt instruments. Approximately $7.2 million of the pre-tax amount included in accumulated other comprehensive income (loss) in shareholders’ equity at March 31, 2014 will be recognized to net income over the next 12 months as the underlying hedged transactions are realized.
11. Fair Value Measurements
ASC 820 “Fair Value Measurements and Disclosures” defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
| |
• | Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. |
| |
• | Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. |
| |
• | Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. |
The following table summarizes the basis used to measure the Company’s financial assets at fair value on a recurring basis in the balance sheet at March 31, 2014 and December 31, 2013:
|
| | | | | | | | | | | | | | | |
| Basis of Fair Value Measurements |
| Balance at March 31, 2014 | | Level 1 | | Level 2 | | Level 3 |
Money market investment | $ | 22,669 |
| | $ | 22,669 |
| | $ | — |
| | $ | — |
|
Available for sale securities | 3,341 |
| | 3,341 |
| | — |
| | — |
|
|
| | | | | | | | | | | | | | | |
| Basis of Fair Value Measurements |
| Balance at December 31, 2013 | | Level 1 | | Level 2 | | Level 3 |
Money market investment | $ | 27,871 |
| | $ | 27,871 |
| | $ | — |
| | $ | — |
|
Available for sale securities | 3,255 |
| | 3,255 |
| | — |
| | — |
|
There were no transfers of assets or liabilities between Level 1 and Level 2 during the quarter ended March 31, 2014 or the year ended December 31, 2013.
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
The carrying value of our cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair values because of the short term nature of these instruments. At March 31, 2014, the fair value of the outstanding indebtedness under our Revolving Facility, 2.58% Senior Euro Notes, 4.5% Senior Notes and 4.2% Senior Notes, based on quoted market prices and current market rates for debt with similar credit risk and maturity, was approximately $801.1 million compared to the carrying value of $776.5 million. This fair value measurement is classified as Level 2 within the fair value hierarchy since it is determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to ours.
12. Other Comprehensive Income (Loss)
The components of other comprehensive income (loss) are as follows:
|
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, 2014 | | Three Months Ended March 31, 2013 |
| Pre-tax | | Tax | | Net of tax | | Pre-tax | | Tax | | Net of tax |
Cumulative translation adjustment | $ | 284 |
| | $ | — |
| | $ | 284 |
| | $ | (27,253 | ) | | $ | — |
| | $ | (27,253 | ) |
Pension and other postretirement adjustments | 679 |
| | (240 | ) | | 439 |
| | 1,935 |
| | (662 | ) | | 1,273 |
|
Reclassification adjustments for derivatives | 1,820 |
| | (663 | ) | | 1,157 |
| | 1,872 |
| | (682 | ) | | 1,190 |
|
Total other comprehensive income (loss) | $ | 2,783 |
| | $ | (903 | ) | | $ | 1,880 |
| | $ | (23,446 | ) | | $ | (1,344 | ) | | $ | (24,790 | ) |
The following table summarizes the amounts reclassified from accumulated other comprehensive income to net income during the three months ended March 31, 2014 and 2013:
|
| | | | | | | | | |
| Three Months Ended March 31, | | |
| 2014 | | 2013 | | Income Statement Caption |
Pension and other postretirement plans: | | | | | |
Amortization of service cost | $ | 679 |
| | $ | 1,935 |
| | Selling, general and administrative expense |
Total before tax | 679 |
| | 1,935 |
| | |
Provision for income taxes | (240 | ) | | (662 | ) | | |
Total net of tax | $ | 439 |
| | $ | 1,273 |
| | |
Derivatives: | | | | | |
Reclassification adjustments | $ | 1,820 |
| | $ | 1,872 |
| | Interest expense |
Total before tax | 1,820 |
| | 1,872 |
| | |
Provision for income taxes | (663 | ) | | (682 | ) | | |
Total net of tax | $ | 1,157 |
| | $ | 1,190 |
| | |
13. Common and Preferred Stock
On November 8, 2013, the Company’s Board of Directors approved a $300.0 million increase in the authorized level for repurchases of common stock. Repurchases under the program will be funded with future cash flow generation or cash available under the Revolving Facility. During the first three months of 2014, the Company purchased a total of 0.6 million shares at a cost of $40.1 million, of which $2.6 million was settled in April 2014. During the first three months of 2013, the Company purchased 0.7 million shares at a cost of $35.7 million, of which $2.6 million was settled in April 2013. As of March 31, 2014, the Company had $327.8 million available under the authorized share repurchase programs.
At March 31, 2014 and December 31, 2013, the Company had 150 million shares of authorized common stock, with a par value of $.01 per share, and 5 million shares of authorized preferred stock, with a par value of $.01 per share. No preferred stock was outstanding at March 31, 2014 or December 31, 2013.
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
14. Share-Based Compensation
During the three months ended March 31, 2014, the Company granted approximately 0.5 million stock options, 0.1 million unvested shares and 0.1 million performance share units. During the three months ended March 31, 2013 the company granted approximately 0.6 million stock options, 0.2 million unvested shares and 0.1 million performance share units.
Weighted average option fair values and assumptions for the periods specified are disclosed below. The fair value of each option grant was estimated on the date of the grant using the Binomial lattice option pricing model.
|
| | | |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Weighted average fair value of option grants | $19.53 | | $12.85 |
Dividend yield | 1.26% | | 1.57% |
Volatility | 30.36% | | 30.94% |
Risk-free forward interest rate | 0.12%-4.69% | | 0.17%-4.10% |
Expected life (in years) | 5.89 | | 5.87 |
Weighted average performance share unit fair values and assumptions for the period specified are disclosed below. The performance share units are market condition awards and have been assessed at fair value on the date of grant using a Monte Carlo simulation model.
|
| | | |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Weighted average fair value of performance share units | $94.55 | | $50.45 |
Dividend yield | 0.00% | | 0.00% |
Volatility | 26.41% | | 28.99% |
Risk-free forward interest rate | 0.65% | | 0.40% |
Expected life (in years) | 2.88 | | 2.87 |
Total compensation cost for stock options is as follows:
|
| | | | | | | |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Cost of goods sold | $ | 242 |
| | $ | 192 |
|
Selling, general and administrative expenses | 2,190 |
| | 2,169 |
|
Total expense before income taxes | 2,432 |
| | 2,361 |
|
Income tax benefit | (755 | ) | | (737 | ) |
Total expense after income taxes | $ | 1,677 |
| | $ | 1,624 |
|
Total compensation cost for unvested shares is as follows:
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
|
| | | | | | | |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Cost of goods sold | $ | 472 |
| | $ | 402 |
|
Selling, general and administrative expenses | 2,746 |
| | 2,660 |
|
Total expense before income taxes | 3,218 |
| | 3,062 |
|
Income tax benefit | (687 | ) | | (715 | ) |
Total expense after income taxes | $ | 2,531 |
| | $ | 2,347 |
|
Total compensation cost for performance share units is as follows:
|
| | | | | | | |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Cost of goods sold | $ | — |
| | $ | — |
|
Selling, general and administrative expenses | 661 |
| | 189 |
|
Total expense before income taxes | 661 |
| | 189 |
|
Income tax benefit | (186 | ) | | (37 | ) |
Total expense after income taxes | $ | 475 |
| | $ | 152 |
|
The Company’s policy is to recognize compensation cost on a straight-line basis, assuming forfeitures, over the requisite service period for the entire award. Classification of stock compensation cost within the Consolidated Statements of Operations is consistent with classification of cash compensation for the same employees.
As of March 31, 2014, there was $14.1 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.6 years, $16.2 million of total unrecognized compensation cost related to unvested shares/units that is expected to be recognized over a weighted-average period of 1.2 years, and $7.8 million of total unrecognized compensation cost related to performance share units that is expected to be recognized over a weighted-average period of 1.4 years.
A summary of the Company’s stock option activity as of March 31, 2014, and changes during the three months ended March 31, 2014 is presented in the following table:
|
| | | | | | | | | | | | |
Stock Options | Shares | | Weighted Average Price | | Weighted-Average Remaining Contractual Term | | Aggregate Intrinsic Value |
Outstanding at January 1, 2014 | 2,516,618 |
| | $ | 39.60 |
| | 6.87 | | $ | 86,200,655 |
|
Granted | 486,505 |
| | 72.74 |
| | | | |
Exercised | (180,617 | ) | | 34.08 |
| | | | |
Forfeited/Expired | (50,949 | ) | | 45.93 |
| | | | |
Outstanding at March 31, 2014 | 2,771,557 |
| | $ | 45.66 |
| | 7.26 | | $ | 75,477,956 |
|
Vested and expected to vest at March 31, 2014 | 2,603,891 |
| | $ | 44.74 |
| | 7.13 | | $ | 73,299,119 |
|
Exercisable at March 31, 2014 | 1,428,590 |
| | $ | 35.99 |
| | 5.78 | | $ | 52,718,583 |
|
15. Retirement Benefits
The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans and other postretirement plans for its employees. The following tables provide the components of net periodic benefit cost for its major defined benefit plans and its other postretirement plans.
IDEX CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands except share data and where otherwise indicated)
(unaudited)
|
| | | | | | | | | | | | | | | |
| Pension Benefits |
| Three Months Ended March 31, |
| 2014 | | 2013 |
| U.S. | | Non-U.S. | | U.S. | | Non-U.S. |
Service cost | $ | 323 |
| | $ | 374 |
| | $ | 437 |
| | $ | 339 |
|
Interest cost | 1,053 |
| | 599 |
| | 943 |
| | 519 |
|
Expected return on plan assets | (1,408 | ) | | (327 | ) | | (1,353 | ) | | (256 | ) |
Net amortization | 699 |
| | 219 |
| | 1,614 |
| | 230 |
|
Net periodic benefit cost | $ | 667 |
| | $ | 865 |
| | $ | 1,641 |
| | $ | 832 |
|
|
| | | | | | | |
| Other Postretirement Benefits |
| Three Months Ended March 31, |
| 2014 | | 2013 |
Service cost | $ | 178 |
| | $ | 242 |
|
Interest cost | 233 |
| | 227 |
|
Net amortization | (118 | ) | | 6 |
|
Net periodic benefit cost | $ | 293 |
| | $ | 475 |
|
The Company previously disclosed in its financial statements for the year ended December 31, 2013, that it expected to contribute approximately $2.8 million to its defined benefit plans and $0.9 million to its other postretirement benefit plans in 2014. As of March 31, 2014, $0.6 million of contributions have been made to the defined benefit plans and $0.2 million has been made to its other postretirement benefit plans. The Company presently anticipates contributing up to an additional $2.9 million in 2014 to fund these plans.
16. Legal Proceedings
The Company is party to various legal proceedings arising in the ordinary course of business, none of which are expected to have a material impact on its business, financial condition, results of operations or cash flows.
17. Income Taxes
The Company’s provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes increased to $29.7 million in the first quarter of 2014 from $24.1 million in the first quarter of 2013. The effective tax rate increased to 28.5% for the first quarter of 2014 compared to 28.2% in the first quarter of 2013 due to the mix of global pre-tax income among jurisdictions. Additionally, the current quarter tax rate was favorably impacted by settlements with taxing authorities primarily related to purchase price adjustments for prior period acquisitions and the comparable quarter tax rate in the prior year was favorably impacted by the enactment of the American Taxpayer Relief Act of 2012 on January 2, 2013, which reinstated the U.S. R&D credit retroactively to January 1, 2012.
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction, and various state and foreign jurisdictions. Due to the potential for resolution of federal, state and foreign examinations, and the expiration of various statutes of limitation, it is reasonably possible that the Company’s gross unrecognized tax benefits balance may change within the next twelve months by a range of zero to $1.0 million.
18. Subsequent Events
On April 28, 2014, the Company acquired Aegis Flow Technologies ("Aegis") for cash consideration of approximately $26.0 million. Aegis, located in Geismar, Louisiana, is a leader in the design, manufacture and sale of specialty chemical processing valves. Aegis has annual revenues of approximately $15.0 million and will operate as part of the Chemical, Food and Process platform within the Fluid & Metering Technologies segment.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Cautionary Statement Under the Private Securities Litigation Reform Act
This quarterly report on Form 10-Q, including the “Overview and Outlook” and the “Liquidity and Capital Resources” sections of this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to, among other things, operating results and are indicated by words or phrases such as “expects,” "anticipates," “should,” “will,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those statements. The risks and uncertainties include, but are not limited to, those risks and uncertainties identified under the heading “Risk Factors” in item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, and information contained in subsequent reports filed by IDEX with the Securities and Exchange Commission. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.
Overview and Outlook
IDEX is an applied solutions company specializing in fluid and metering technologies, health and science technologies, and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets to a wide range of industries throughout the world. Accordingly, IDEX's businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business and by the relationship of the U.S. dollar to other currencies. Levels of capacity utilization and capital spending in certain industries and overall industrial activity are among the factors that influence the demand for IDEX’s products.
The Company has three reportable business segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products. Within our three reportable segments, the Company maintains six platforms, where we will invest in organic growth and acquisitions with a strategic view towards a platform with the potential for at least $500 million in revenue, and seven groups, where we will focus on organic growth and strategic acquisitions. The Fluid & Metering Technologies segment contains the Energy, Water (comprised of Water Services & Technology and Diaphragm & Dosing Pump Technology), and Chemical, Food & Process platforms as well as the Agricultural group (comprised of Banjo). The Health & Science Technologies segment contains the IDEX Optics & Photonics, Scientific Fluidics and Material Processing Technologies platforms, as well as the Sealing Solutions and the Industrial (comprised of Micropump and Gast) groups. The Fire & Safety/Diversified Products segment is comprised of the Dispensing, Rescue, Band-It, and Fire Suppression groups. Each platform/group is comprised of one or more of our 15 reporting units: five reporting units within Fluid & Metering Technologies (Energy; Chemical, Food, & Process; Water Services & Technology; Banjo; Diaphragm & Dosing Pump Technology); six reporting units within Health & Science Technologies (IDEX Optics and Photonics; Scientific Fluidics; Material Processing Technology; Sealing Solutions; Micropump; and Gast); and four reporting units within Fire & Safety/Diversified Products (Dispensing, Rescue, Band-It, and Fire Suppression).
The Fluid & Metering Technologies segment designs, produces and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems and provides flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agricultural and energy industries.
The Health & Science Technologies segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets, and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications.
The Fire & Safety/Diversified Products segment produces firefighting pumps and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, and engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications, precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world.
Some of our key financial highlights for the three months ended March 31, 2014 are as follows:
| |
• | Sales of $544.0 million increased 10%; organic sales — excluding acquisitions and foreign currency translation — were up 8%. |
| |
• | Operating income of $113.8 million increased 20% |
| |
• | Net income increased 22% to $74.5 million. |
| |
• | Diluted EPS of $0.91 increased 17 cents, or 23%, compared to 2013. |
Our projected second quarter 2014 EPS is in the range of $0.85 to $0.87. Given the Company’s current outlook and the projection of 4-5% organic revenue growth for the year, we have increased our full year EPS outlook; we now expect full year 2014 diluted EPS of $3.38 to $3.45.
Results of Operations
The following is a discussion and analysis of our results of operations for the three month periods ended March 31, 2014 and 2013. Segment operating income excludes unallocated corporate operating expenses.
Management’s primary measurements of segment performance are sales, operating income, and operating margin. In addition, due to the highly acquisitive nature of the Company, the determination of operating income includes amortization of acquired intangible assets and, as a result, management reviews depreciation and amortization as a percentage of sales. These measures are monitored by management and significant changes in operating results versus current trends in end markets and variances from forecasts are analyzed with segment management.
In this report, references to organic sales, a non-GAAP measure, refers to sales from continuing operations calculated according to generally accepted accounting principles in the United States but excludes (1) sales from acquired businesses during the first twelve months of ownership and (2) the impact of foreign currency translation. The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Management believes that reporting organic sales provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior and future periods and to our peers. The Company excludes the effect of foreign currency translation from organic sales because foreign currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions because the nature, size, and number of acquisitions can vary dramatically from period to period and between the Company and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult. In addition, this report references EBITDA. This non-GAAP measure has been reconciled to Net income and Operating income in this Item 2 under the heading "Non-GAAP Disclosures." Given the acquisitive nature of the Company management reviews EBITDA. This non-GAAP financial measure provides management with important information about the performance of the Company's businesses by, among other matters, eliminating the impact of higher amortization expense at recently acquired businesses.
Consolidated Results in the Three Months Ended March 31, 2014 Compared with the Same Period of 2013
|
| | | | | | | |
(In thousands) | Three Months Ended March 31, |
| 2014 | | 2013 |
Net sales | $ | 543,996 |
| | $ | 494,448 |
|
Operating income | 113,835 |
| | 94,712 |
|
Operating margin | 20.9 | % | | 19.2 | % |
EBITDA | $ | 133,936 |
| | $ | 115,830 |
|
EBITDA as a percentage of net sales | 24.6 | % | | 23.4 | % |
Depreciation and amortization | $ | 19,257 |
| | $ | 19,839 |
|
Depreciation and amortization as a percentage of net sales | 3.5 | % | | 4.0 | % |
Capital expenditures | $ | 10,809 |
| | $ | 7,625 |
|
Capital expenditures as a percentage of net sales | 2.0 | % | | 1.5 | % |
Sales in the three months ended March 31, 2014 were $544.0 million, a 10% increase from the comparable period last year. This increase reflects an 8% increase in organic sales, a 1% increase from acquisitions (FTL — March 2013) and 1% favorable foreign currency translation. Organic sales to customers outside the U.S. represented approximately 48% of total sales in 2014 compared to 52% during the same period of 2013.
For the first three months of 2014, Fluid & Metering Technologies contributed 41% of sales and 43% of operating income; Health & Science Technologies accounted for 34% of sales and 27% of operating income; and Fire & Safety/Diversified Products represented 25% of sales and 30% of operating income.
Gross profit of $244.4 million in the first three months of 2014 increased $32.4 million, or 15%, from the same period in 2013. Gross margin of 44.9% in the first three months of 2014 increased from 42.9% during the same period in 2013. The increase in gross margin primarily resulted from an increase in volume and benefits from the Company’s structural cost actions taken in prior years.
Selling, general and administrative expenses increased to $130.6 million in the first three months of 2014 from $117.3 million during the same period of 2013. The change reflects an increase of approximately $1.2 million for incremental costs from a full quarter of the FTL acquisition and an increase in volume related expenses of $12.1 million. As a percentage of sales, SG&A expenses were 24.0% for the first three months of 2014 and 23.7% for the same period of 2013.
Operating income of $113.8 million in the first three months of 2014 was up from the $94.7 million recorded during the same period in 2013, primarily reflecting an increase in volume and improved productivity. Operating margin of 20.9% in the first three months of 2014 was up from 19.2% during the same period of 2013, primarily due to volume leverage, productivity, and conversion of the large Dispensing order.
Other income - net of $0.8 million in the first three months of 2014 was down $0.4 million compared with the same period in 2013, primarily due to lower gains on foreign currency transactions.
Interest expense of $10.5 million in the first three months of 2014 was slightly down from $10.6 million in 2013.
The provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes of $29.7 million for the first three months of 2014 increased compared to $24.1 million recorded in the same period of 2013. The effective tax rate increased to 28.5% for the first three months of 2014 compared to 28.2% in the same period of 2013 due to the mix of global pre-tax income among jurisdictions. Additionally, the current quarter tax rate was favorably impacted by settlements with taxing authorities primarily related to purchase price adjustments for prior period acquisitions and the comparable quarter tax rate in the prior year was favorably impacted by the enactment of the American Taxpayer Relief Act of 2012 on January 2, 2013, which reinstated the U.S. R&D credit retroactively to January 1, 2012.
Net income in the first three months of 2014 of $74.5 million increased from $61.3 million during the same period of 2013. Diluted earnings per share in the first three months of 2014 of $0.91 increased $0.17, or 23%, compared with the same period in 2013.
Fluid & Metering Technologies Segment
|
| | | | | | | |
(In thousands) | Three Months Ended March 31, |
| 2014 | | 2013 |
Net sales | $ | 223,361 |
| | $ | 211,755 |
|
Operating income | 56,407 |
| | 48,079 |
|
Operating margin | 25.3 | % | | 22.7 | % |
EBITDA | $ | 63,237 |
| | $ | 55,322 |
|
EBITDA as a percentage of net sales | 28.3 | % | | 26.1 | % |
Depreciation and amortization | $ | 6,552 |
| | $ | 6,960 |
|
Depreciation and amortization as a percentage of net sales | 2.9 | % | | 3.3 | % |
Capital expenditures | $ | 4,009 |
| | $ | 2,776 |
|
Capital expenditures as a percentage of net sales | 1.8 | % | | 1.3 | % |
Sales of $223.4 million increased $11.6 million, or 6%, in the first three months of 2014 compared with the same period of 2013. This reflects a 5% increase in organic sales and 1% favorable foreign currency translation. In the first three months of 2014, organic sales increased 10% domestically and decreased 1% internationally compared to the 2013 period. Organic sales to customers outside the U.S. were approximately 43% of total segment sales during the first three months of 2014, compared with 45% during the same period in 2013.
Sales within our Energy platform increased in the first three months of 2014 compared to the same period of 2013, due to the benefit from larger than anticipated fuel consumption from the extended winter, and the strength of OEM truck builds and North American electronic retrofits. Sales within our Chemical, Food & Process platform increased compared to the first three
months of 2013 based on stable general industrial demand, partially offset by project timing delays in emerging markets. Sales within our Agriculture group improved in spite of the extended winter. Diaphragm & Dosing Pump Technology platform sales increased compared to the first three months of 2013 due to increased demand in the oil and gas markets, and increased stability in the European and Asian markets. Sales in our Water Services & Technology group increased slightly in the first three months of 2014 compared to the same period in 2013 based on the continued improvement in municipal spending, driven by demand in North America, Japan and Europe.
Operating income and operating margin of $56.4 million and 25.3%, respectively, were higher than the $48.1 million and 22.7% recorded in the first three months of 2013, primarily due to increased volume, operational execution, and productivity.
Health & Science Technologies Segment
|
| | | | | | | |
(In thousands) | Three Months Ended March 31, |
| 2014 | | 2013 |
Net sales | $ | 186,375 |
| | $ | 172,868 |
|
Operating income | 36,229 |
| | 32,267 |
|
Operating margin | 19.4 | % | | 18.7 | % |
EBITDA | $ | 46,951 |
| | $ | 43,315 |
|
EBITDA as a percentage of net sales | 25.2 | % | | 25.1 | % |
Depreciation and amortization | $ | 10,709 |
| | $ | 10,792 |
|
Depreciation and amortization as a percentage of net sales | 5.7 | % | | 6.2 | % |
Capital expenditures | $ | 3,509 |
| | $ | 2,786 |
|
Capital expenditures as a percentage of net sales | 1.9 | % | | 1.6 | % |
Sales of $186.4 million increased $13.5 million, or 8%, in the first three months of 2014 compared with the same period in 2013. This reflects 5% organic revenue growth and 3% growth from acquisitions (FTL - March 2013). In the first three months of 2014, organic sales increased 13% domestically and decreased 1% internationally. Organic sales to customers outside the U.S. were approximately 52% of total segment sales in the first three months of 2014 compared with 53% during the same period in 2013.
Sales within our Material Process Technologies platform increased compared to the first three months of 2013 due to large pharmaceutical project shipments in North America from orders placed in 2013. Sales within our Scientific Fluidics platform increased compared to the first three months of 2013 due to gaining market share through new product introductions and the continued strengthening of core analytical instrumentation and in vitro diagnostics markets. Sales within the Sealing Solutions group increased compared to the first three months of 2013 due to the acquisition of FTL in March 2013 as well as continued strong sales in North American energy markets. Sales within our Optics and Photonics platform decreased slightly compared to the first three months of 2013 due to softness in military spending as well as the decision to exit certain product lines. Sales within our Industrial group increased compared to the first three months of 2013 due to greater stability in North American distributor sales and our team's ability to capture market share.
Operating income and operating margin of $36.2 million and 19.4%, respectively, in the first three months of 2014 were up from the $32.3 million and 18.7% recorded in the same period of 2013, primarily due to increased volume and productivity.
Fire & Safety/Diversified Products Segment
|
| | | | | | | |
(In thousands) | Three Months Ended March 31, |
| 2014 | | 2013 |
Net sales | $ | 137,284 |
| | $ | 111,513 |
|
Operating income | 39,648 |
| | 28,232 |
|
Operating margin | 28.9 | % | | 25.3 | % |
EBITDA | $ | 41,561 |
| | $ | 30,291 |
|
EBITDA as a percentage of net sales | 30.3 | % | | 27.2 | % |
Depreciation and amortization | $ | 1,680 |
| | $ | 1,708 |
|
Depreciation and amortization as a percentage of net sales | 1.2 | % | | 1.5 | % |
Capital expenditures | $ | 1,807 |
| | $ | 1,480 |
|
Capital expenditures as a percentage of net sales | 1.3 | % | | 1.3 | % |
Sales of $137.3 million increased $25.8 million, or 23%, in the first three months of 2014 compared with the same period in 2013. This reflects 22% organic growth and 1% favorable foreign currency translation. In the first three months of 2014, organic sales increased 55% domestically and decreased 2% internationally, year over year. Organic sales to customers outside the U.S. were approximately 47% of total segment sales in the first three months of 2014 compared to 58% during the same period of 2013.
Sales within our Dispensing group increased as a result of fulfilling a large dispensing order, combined with modest growth in the core North American and European markets. Sales were stable within our Band-It group, driven by strong expansion in China and cable management project orders. Sales within our Fire Suppression group increased due to demand for power facility trailers, and strong project orders from China. Sales within our Rescue group decreased due to prolonged decision making on projects in China and Europe.
Operating income and operating margin of $39.6 million and 28.9%, respectively, in the first three months of 2014 were higher than the $28.2 million and 25.3% recorded in the first three months of 2013, primarily due to volume leverage and the fulfillment of the large Dispensing order.
Liquidity and Capital Resources
At March 31, 2014, working capital was $749.4 million and the current ratio was 3.4 to 1. Cash flows from operating activities for the first three months of 2014 increased $2.0 million, or 2.8%, to $74.2 million compared to the first three months of 2013, mainly due to higher earnings partially offset by an increase in operating working capital.
Cash flows provided by operating activities were more than adequate to fund capital expenditures of $10.8 million and $7.6 million in the first three months of 2014 and 2013, respectively. Capital expenditures were generally for machinery and equipment that improved productivity, tooling, business system technology and replacement of equipment and facilities. Management believes that the Company has sufficient capacity in its plants and equipment to meet expected needs for future growth.
The Company maintains the Revolving Facility, which is a $700.0 million unsecured, multi-currency bank credit facility expiring on June 27, 2016. At March 31, 2014, there were $17.0 million of outstanding borrowings under the Revolving Facility and outstanding letters of credit totaled approximately $7.9 million. The net available borrowing capacity under the Revolving Facility at March 31, 2014, was approximately $675.1 million. Borrowings under the Revolving Facility bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, in each case, an applicable margin. Such applicable margin is based on the Company’s senior, unsecured, long-term debt rating and can range from .875% to 1.70%. Based on the Company’s credit rating at March 31, 2014, the applicable margin was 1.05%. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the maturity date of the borrowing, or quarterly from the effective date for borrowings exceeding three months. An annual Revolving Facility fee, also based on the Company’s credit rating, is currently 20 basis points and is payable quarterly.
There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and 2.58% Senior Euro Notes. The most restrictive financial covenants under these debt instruments require a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.25 to 1. At March 31, 2014, the Company was in compliance with both of these financial covenants, as the Company’s interest coverage ratio was 12.20 to 1 and the leverage ratio was 1.58 to 1. There are no financial covenants relating to the 4.5% Senior Notes or 4.2% Senior Notes; however, both are subject to cross-default provisions.
On November 8, 2013, the Company’s Board of Directors approved a $300.0 million increase in the authorized level for repurchases of common stock. Repurchases under the program will be funded with future cash flow generation. During the first three months of 2014, the Company purchased a total of 0.6 million shares at a cost of $40.1 million, of which $2.6 million was settled in April 2014. As of March 31, 2014, the Company had $327.8 million available under the authorized share repurchase programs.
The Company believes current cash, cash from operations and cash available under the Revolving Facility will be sufficient to meet its operating cash requirements, planned capital expenditures, interest on all borrowings, pension and postretirement funding requirements, expected share repurchases and annual dividend payments to holders of the Company’s stock for the remainder of 2014. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings. As of March 31, 2014, $17.0 million was outstanding under the Revolving Facility, with $7.9 million of outstanding letters of credit, resulting in net available borrowing capacity under the Revolving Facility at March 31, 2014 of approximately $675.1 million.
Non-GAAP Disclosures
The following is a reconciliation of EBITDA to the comparable measures of net income and operating income, as determined in accordance with U.S. GAAP. We have reconciled consolidated EBITDA to net income and we have reconciled segment EBITDA to operating income, as we do not allocate interest and income taxes to our segments. EBITDA means earnings before interest, income taxes, depreciation and amortization. Given the acquisitive nature of the Company which results in a higher level of amortization expense at recently acquired businesses, management uses EBITDA, in addition to operating income, to provide it with another way to measure financial performance of businesses across our three segments. Management also uses EBITDA for enterprise valuation purposes. We believe that EBITDA is also useful to some investors as an indicator of the strength and performance of the Company's and its segments ongoing business operations and a way to evaluate and compare operating performance and value companies within our industry. However, it should not be considered as an alternative to net income, operating income or any other items calculated in accordance with U.S. GAAP. The definition of EBITDA used here may differ from that used by other companies.
|
| | | | | | | | |
Consolidated | | Three Months Ended March 31, |
| | 2014 | | 2013 |
Net income | | $ | 74,548 |
| | $ | 61,300 |
|
+ Income taxes | | 29,674 |
| | 24,134 |
|
+ Interest expense | | 10,457 |
| | 10,557 |
|
+ Depreciation & amortization | | 19,257 |
| | 19,839 |
|
EBITDA | | $ | 133,936 |
| | $ | 115,830 |
|
| | | | |
Net sales | | $ | 543,996 |
| | $ | 494,448 |
|
EBITDA as a percentage of net sales | | 24.6 | % | | 23.4 | % |
|
| | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended March 31, |
| | 2014 | | 2013 |
| | FMT | | HST | | FSD | | FMT | | HST | | FSD |
Operating income | | $ | 56,407 |
| | $ | 36,229 |
| | $ | 39,648 |
| | $ | 48,079 |
| | $ | 32,267 |
| | $ | 28,232 |
|
+ Other income | | 278 |
| | 13 |
| | 233 |
| | 283 |
| | 256 |
| | 351 |
|
+ Depreciation & amortization | | 6,552 |
| | 10,709 |
| | 1,680 |
| | 6,960 |
| | 10,792 |
| | 1,708 |
|
EBITDA | | $ | 63,237 |
| | $ | 46,951 |
| | $ | 41,561 |
| | $ | 55,322 |
| | $ | 43,315 |
| | $ | 30,291 |
|
| | | | | | | | | | | | |
Net sales | | $ | 223,361 |
| | $ | 186,375 |
| | $ | 137,284 |
| | $ | 211,755 |
| | $ | 172,868 |
| | $ | 111,513 |
|
EBITDA as a percentage of net sales | | 28.3 | % | | 25.2 | % | | 30.3 | % | | 26.1 | % | | 25.1 | % | | 27.2 | % |
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
The Company is subject to market risk associated with changes in foreign currency exchange rates and interest rates. The Company may, from time to time, enter into foreign currency forward contracts and interest rate swaps on its debt when it believes there is a financial advantage in doing so. A treasury risk management policy, adopted by the Board of Directors, provides for
procedures and controls over derivative financial and commodity instruments, including foreign currency forward contracts and interest rate swaps. Under the policy, the Company does not use derivative financial or commodity instruments for trading purposes, and the use of these instruments is subject to strict approvals by senior officers. Typically, the use of derivative instruments is limited to foreign currency forward contracts and interest rate swaps on the Company’s outstanding long-term debt.
The Company’s foreign currency exchange rate risk is limited principally to the Euro, British Pound, Canadian Dollar, Japanese Yen, Indian Rupee and Chinese Renminbi. The Company manages its foreign exchange risk principally through invoicing customers in the same currency as the source of products. The effect of transaction gains and losses is reported within other income-net on the Consolidated Statements of Operations.
The Company’s interest rate exposure is primarily related to the $780.2 million of total debt outstanding at March 31, 2014. Approximately 2% of the debt is priced at interest rates that float with the market. A 50 basis point movement in the interest rate on the floating rate debt would result in an approximate $0.1 million annualized increase or decrease in interest expense and cash flows. The remaining debt is fixed rate debt.
Item 4. Controls and Procedures.
The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
As required by Rule 13a-15(b) promulgated under the Securities Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and the Company’s Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company’s Chief Executive Officer and Chief Financial Officer concluded as of March 31, 2014, that the Company’s disclosure controls and procedures were effective.
There has been no change in the Company’s internal controls over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal controls over financial reporting.
PART II. OTHER INFORMATION
| |
Item 1. | Legal Proceedings. |
The Company and six of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. These components were acquired from third party suppliers, and were not manufactured by any of the subsidiaries. To date, the majority of the Company’s settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover these settlements and legal costs, or how insurers may respond to claims that are tendered to them. Claims have been filed in jurisdictions throughout the United States. Most of the claims resolved to date have been dismissed without payment. The balance have been settled for various insignificant amounts. Only one case has been tried, resulting in a verdict for the Company’s business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.
The Company is also party to various other legal proceedings arising in the ordinary course of business, none of which is expected to have a material adverse effect on its business, financial condition, results of operations or cash flows.
| |
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds. |
The following table provides information about the Company’s purchases of its common stock during the quarter ended March 31, 2014:
|
| | | | | | | | | | | | | |
Period | Total Number of Shares Purchased | | Average Price Paid per Share | | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) | | Maximum Dollar Value that May Yet be Purchased Under the Plans or Programs(1) |
January 1, 2014 to January 31, 2014 | 215,071 |
| | $ | 72.48 |
| | 215,071 |
| | $ | 352,346,341 |
|
February 1, 2014 to February 28, 2014 | 115,978 |
| | $ | 71.84 |
| | 115,978 |
| | $ | 344,014,517 |
|
March 1, 2014 to March 31, 2014 | 220,099 |
| | $ | 73.66 |
| | 220,099 |
| | $ | 327,802,105 |
|
Total | 551,148 |
| | $ | 72.66 |
| | 551,148 |
| | $ | 327,802,105 |
|
| |
(1) | On November 8, 2013, the Company announced that its Board of Directors had increased the authorized level for repurchases of its common stock by approximately $300.0 million. This followed the prior Board of Directors approved repurchase authorizations of $200.0 million, announced by the Company on October 22, 2012; $50.0 million, announced by the Company on December 6, 2011; and the original repurchase authorization of $125.0 million announced by the Company on April 21, 2008. |
The exhibits listed in the accompanying “Exhibit Index” are filed or furnished as part of this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
| | |
| IDEX Corporation |
| | |
| By: | /s/ HEATH A. MITTS |
| | Heath A. Mitts |
| | Senior Vice President and Chief Financial Officer (Principal Financial Officer) |
| | |
| By: | /s/ MICHAEL J. YATES |
| | Michael J. Yates |
| | Vice President and Chief Accounting Officer (Principal Accounting Officer) |
Date: April 29, 2014
EXHIBIT INDEX
|
| | |
Exhibit Number | | Description |
3.1 | | Restated Certificate of Incorporation of IDEX Corporation (incorporated by reference to Exhibit No. 3.1 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on April 21, 1988) |
| |
3.1(a) | | Amendment to Restated Certificate of Incorporation of IDEX Corporation (incorporated by reference to Exhibit No. 3.1(a) to the Quarterly Report of IDEX on Form 10-Q for the quarter ended March 31, 1996, Commission File No. 1-10235) |
| |
3.1(b) | | Amendment to Restated Certificate of Incorporation of IDEX Corporation (incorporated by reference to Exhibit No. 3.1(b) to the Current Report of IDEX on Form 8-K dated March 24, 2005, Commission File No. 1-10235) |
| |
3.2 | | Amended and Restated By-Laws of IDEX Corporation (incorporated by reference to Exhibit No. 3.1 to the Current Report of IDEX Corporation on form 8-K filed November 14, 2011, Commission File No. 1-10235) |
| | |
3.2(a) | | Amended and Restated Article III, Section 13 of the Amended and Restated By-Laws of IDEX Corporation (incorporated by reference to Exhibit No. 3.2(a) to Post-Effective Amendment No. 3 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on February 12, 1990) |
| |
*10.1 | | Form of IDEX Corporation Performance Share Unit Award Agreement |
| | |
*31.1 | | Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002 |
| |
*31.2 | | Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002 |
| |
*32.1 | | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 |
| |
*32.2 | | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 |
| |
*101 | | The following financial information from IDEX Corporation's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, formatted in XBRL includes: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Earnings, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statement of Shareholders’ Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements. |
| | |
* Filed Herewith |
IEX-2014.03.31-EX10.1
Exhibit 10.1
Plan: IDEX Corporation Incentive Award Plan
As Amended and Restated effective April 6, 2010
IDEX CORPORATION
PERFORMANCE SHARE UNIT AWARD AGREEMENT
Effective on the Grant Date, you have been granted Performance Share Units (the "Performance Units") providing you the entitlement to receive a share of IDEX Corporation (the "Company" or "IDEX") Common Stock for each Performance Unit that is earned and vested, in accordance with the provisions of this Agreement and the provisions of the IDEX Corporation Incentive Award Plan, as Amended and Restated effective April 6, 2010 (the "Plan"), which is incorporated herein by this reference and made a part of this Agreement.
The number of Performance Units granted, represents a target number of shares that may be earned based upon satisfaction of the target Performance Goal as set forth on Schedule A (the "Target Award"). The actual number of Performance Units earned and vested may be greater or less than the Target Award, or even zero and will be determined based on the Company's actual performance level achieved as set forth on Schedule A.
In addition to the Performance Units, you are also entitled to receive Dividend Equivalents on each Performance Unit actually earned and vested equal to the amount of dividend which would have been paid on a share of Common Stock for which a record date falls during the Performance Period, without interest thereon. If the dividend on Common Stock is paid in property other than cash, the Compensation Committee in its sole and absolute discretion will determine the fair market value of such property for purposes of paying the Dividend Equivalents.
The "Performance Period" for the Performance Units is the three year period beginning January 1 (“Beginning Date”) and ending December 31 (“End Date”) as set forth on Schedule A, except as otherwise provided below.
In the event of the termination of your service to the Company or any corporation or other entity of which a majority of the outstanding voting stock or voting power is beneficially owned by the Company (its "Subsidiary"), prior to the End Date for any reason, whether such termination is occasioned by you, by the Company or a Subsidiary, with or without cause or by mutual agreement ("Termination of Service"), your right to earn or vest in your Performance Units and Dividend Equivalents will terminate effective as of the date of Termination of Service and your Performance Units and all Dividend Equivalents thereon will be automatically cancelled and forfeited. If your employment or service is in a jurisdiction which requires under applicable statute or common law a notice period for termination or a period of pay in lieu of such notice (each, the "Notice Period"), you have no rights to earn or vest in your Performance Units or to receive Dividend Equivalents during the Notice Period.
Notwithstanding the foregoing, the Performance Units and any Dividend Equivalents thereon shall be fully vested upon your Termination of Service by reason of death, Disability, or Retirement and the Performance Units and Dividend Equivalents thereon earned will be determined based upon the performance level achieved with respect to the Performance Goal as set forth on Schedule A from the Beginning Date through the December 31 following your Termination of Service, which for this purpose shall be the End Date of the Performance Period.
If you terminate employment with the Company or any of its Subsidiaries as an employee, but you continue to provide bona fide services under a written agreement with the Company or any of its Subsidiaries as a consultant or contractor you will still be considered to have a Termination of Service upon termination of your employment, unless you enter into a written agreement with the Company explicitly providing that you will not have a Termination of Service, for this plan only, while performing the non-employee services.
2014 – 8 PSU Agreement Revised: 02/14/2014
In all cases, Termination of Service will be interpreted and determined in a manner consistent with the requirements of Section 409A of the Internal Revenue Code.
For the purposes of this Agreement: (i) "Disability" means that you could qualify to receive long-term disability payments under the Company's long-term disability insurance program, as it may be amended from time to time, (ii) “Retirement” means your Termination of Service on or after accruing at least five Years of Service with the Company or a Subsidiary after being acquired by the Company, and attaining an age of at least 50, if the sum of your age and Years of Service is at least 70, (iii) “Years of Service” means the number of continuous full years of employment with the Company or any of its Subsidiaries.
Upon Change in Control, as defined in the Plan, Performance Units and Dividend Equivalents thereon shall be deemed fully earned and vested based upon the performance level achieved from the Beginning Date through the date of the Change in Control, which for this purpose will be deemed to be the End Date of the Performance Period.
A share of Common Stock will be issued to you in payment of each Performance Units that is earned and vested as soon as practicable following the End Date of the relevant Performance Period, but in no event later than 60 days after, the End Date of the relevant Performance Period. An amount equal to the Dividend Equivalents on each earned and vested Performance Unit shall be paid in cash as soon as practicable following, but in no event later than 60 days after the End Date of the relevant Performance Period.
The Performance Units and Dividend Equivalents are not transferable except by will or the laws of descent and distribution. Until the Common Stock is issued upon settlement of the Performance Units you will not be deemed for any purpose to be, or have rights as, a Company shareholder by virtue of this award.
The Company has the authority to deduct or withhold, or require you to remit to the Company, an amount sufficient to satisfy applicable federal, state, local and foreign taxes arising from the receipt of the shares of Common Stock upon settlement of the Performance Units or of cash upon payment of Dividend Equivalents. You may satisfy your tax obligation, in whole or in part, by either: (i) electing to have the Company withhold cash payable, or shares otherwise to be delivered with a fair market value equal to the minimum amount of the tax withholding obligation; (ii) surrendering to the Company previously owned Common Stock with a fair market value equal to the minimum amount of the tax withholding obligation or (iii) by deduction from salary or any other payment payable to you at any time on or after the day an income tax charge arises in respect of the shares.
You acknowledge that all employees, including corporate officers, of IDEX are prohibited from engaging in any transaction in which they may profit from short-term speculative swings in the value of the company securities (“hedging”) and agree not to engage in any hedging transactions. For this purpose, “hedging” includes “short-sales” (selling borrowed securities which the seller hopes can be purchased at a lower price in the future) or “short sales against the box” (selling owned, but not delivered securities), “put” and “call” options (publicly available rights to sell or buy securities within a certain period of time at a specified price or the like), and other hedging transactions designed to minimize the risk inherent in owning IDEX stock, such as zero-cost collars and forward sales contracts.
Consistent with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and to the extent not in violation of any applicable law, IDEX reserves the right to recover from current and/or former key employees any wrongfully earned performance-based compensation, including stock-based awards, upon the determination by the Compensation Committee of the following:
| |
(a) | there is a restatement of Company financials, due to the material noncompliance with any financial reporting requirement, |
| |
(b) | the cash incentive or equity compensation to be recouped was calculated on, or its realized value affected by, the financial results that were subsequently restated, |
| |
(c) | the cash incentive or equity compensation would have been less valuable than what was actually awarded or paid based upon the application of the correct financial results, and |
| |
(d) | the pay affected by the calculation was earned or awarded within three years of the determination of the necessary restatement |
2014 – 8 PSU Agreement Revised: 02/14/2014
The Compensation Committee has exclusive authority to modify, interpret and enforce this provision in compliance with all regulations.
You acknowledge and consent to the collection, use, processing and transfer of personal data as described in this paragraph. The Company, its affiliates and your employer hold certain personal information, including your name, home address and telephone number, date of birth, social security number or other employee tax identification number, salary, nationality, job title, any options awarded, cancelled, purchased, vested, unvested or outstanding in your favor, for the purpose of managing and administering your Performance Units and Dividend Equivalents ("Data"). The Company and its affiliates will transfer Data to any third parties assisting the Company in the implementation, administration and management of your Performance Units and Dividend Equivalents. These recipients may be located in the European Economic Area, or elsewhere such as the United States. You authorize them to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing your Performance Units and Dividend Equivalents. You may, at any time, review Data, require any necessary amendments to it or withdraw the consent herein in writing by contacting the Company; however, withdrawing the consent may affect your ability to participate in the Plan and receive Dividend Equivalents or shares of Common Stock upon vesting in the Performance Units.
Your participation in the Plan is voluntary. The value of the Dividend Equivalents, Performance Units or shares of Common Stock received upon vesting in the Performance Units is extraordinary items of compensation outside the scope of your employment contract, if any. As such, the Dividend Equivalents, Performance Units and Common Stock received upon vesting of the Performance Units are not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pensions or retirement benefits or similar payments unless specifically and otherwise provided. Rather, the awarding of Dividend Equivalents and Performance Units represents a mere investment opportunity.
The Performance Units and Dividend Equivalents are granted under and governed by the terms and conditions of the Plan. You acknowledge and agree that the Plan is discretionary in nature and may be amended, cancelled, or terminated by the Company, in its sole discretion, at any time. The Plan has been introduced voluntarily by the Company and in accordance with the provisions of the Plan may be terminated by the Company at any time. The grant of the Performance Units and Dividend Equivalents are a one-time benefit and does not create any contractual or other right to receive a grant of Performance Units, dividend equivalents or benefits in lieu of Performance Units or dividend equivalents in the future. Future grants of Performance Units and Dividend Equivalents, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of the grant, the number of units and vesting provisions. By execution of this Agreement, you consent to the provisions of the Plan and this Agreement.
All cash payments shall be made as determined by the Committee in either US dollars or the local currency applicable to your jurisdiction, after being converted from a US dollar equivalent based on the exchange rate selected by the Committee.
Defined terms used herein shall have the meaning set forth in the Plan, unless otherwise defined herein.
COMPANY:
IDEX CORPORATION
By: Frank J. Notaro
Vice President - General Counsel and Secretary
2014 – 8 PSU Agreement Revised: 02/14/2014
Schedule A
The number of Performance Units earned and vested will be determined as follows:
Earned Performance Units = Payout Percentage x Target Award
The Payout Percentage is based on IDEX's percentile ranking of its TSR (as defined below) vs. the TSR of the companies in the S&P Midcap 400 Industrial Group with a GICS Sector Code = 20 - Industrials at the end of the Performance Period.
Performance Period: January 1, 2014-December 31, 2016
|
| | |
Performance Level | Performance Goal | Payout Percentage |
| | |
Below Threshold | Achieve Less than 33rd Percentile Performance | 0% |
Threshold | Achieve 33rd Percentile Performance | 33% |
Target | Achieve 50th Percentile Performance | 100% |
High Achievement | Achieve 60th Percentile Performance | 150% |
Achieve 70th Percentile Performance | 200% |
Achieve 80th Percentile Performance | 250% |
Achievement between each performance level will be interpolated on a straight line basis rounded to the nearest whole number; provided that if the actual performance level achieved does not meet Threshold performance (i.e.: if performance is less than 33rd Percentile) then no Performance Units will be earned. The maximum number of Performance Units that may be earned shall be 250% of the Target Award.
Notwithstanding the Payout Percentage indicated above, if IDEX’s TSR for the Performance Period is less than 1.00 (negative TSR), the Payout Percentage will not be greater than 100%, (i.e. a TSR of 0.98 is equal to a -2.0% (absolute negative two percent)).
"TSR" is calculated by dividing the Closing Average Share Value by the Opening Average Share Value at the end of the Performance Period and assuming that all applicable dividends are reinvested on the ex-dividend date. For this purpose:
| |
• | "Closing Average Share Value" means the average closing price of the Common Stock, for the 30 calendar days ending on the last day of the Performance Period (i.e.: December 2, 2016 to December 31, 2016) |
| |
• | "Opening Average Share Value" means the average closing price of the Common Stock, for the 30 calendar days preceding the beginning of the Performance Period (i.e.: for Performance Period with a Beginning Date of January 1, 2014, the Opening Average Share Value would include the calendar days from December 2, 2013 to December 31, 2013) |
2014 – 8 PSU Agreement Revised: 02/14/2014
IEX-2014.03.31-EX31.1
Exhibit 31.1
Certification of Chief Executive Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
I, Andrew K. Silvernail, certify that:
1. I have reviewed this quarterly report on Form 10-Q of IDEX Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
| | |
| | |
| | /s/ ANDREW K. SILVERNAIL |
| | Andrew K. Silvernail |
| | Chairman of the Board and Chief Executive Officer |
Date: April 29, 2014
IEX-2014.03.31-EX31.2
Exhibit 31.2
Certification of Chief Financial Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
I, Heath A. Mitts, certify that:
1. I have reviewed this quarterly report on Form 10-Q of IDEX Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
| | |
| | |
| | /s/ HEATH A. MITTS |
| | Heath A. Mitts |
| | Senior Vice President and Chief Financial Officer |
Date: April 29, 2014
IEX-2014.03.31-EX32.1
Exhibit 32.1
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of IDEX Corporation (the “Company”) hereby certifies, to such officer's knowledge, that:
(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2014 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
| | |
| | |
| | /s/ ANDREW K. SILVERNAIL |
| | Andrew K. Silvernail |
| | Chairman of the Board and Chief Executive Officer |
Date: April 29, 2014
IEX-2014.03.31-EX32.2
Exhibit 32.2
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of IDEX Corporation (the “Company”) hereby certifies, to such officer's knowledge, that:
(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2014 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
| | |
| | |
| | /s/ HEATH A. MITTS |
| | Heath A. Mitts |
| | Senior Vice President and Chief Financial Officer |
Date: April 29, 2014